InflaRx N.V. (IFRX) Stock Forecast

NASDAQ: IFRXAnalyst ratings, price target and estimates.

IFRX analyst forecast

as of October 18, 2026
Analyst consensus
Strong buy
4.67 / 5 from 9 analysts
Price target
$7.68
average of analyst targets
Upside to target
+481.9%
from the latest close
Next earnings
November 9, 2026
EPS estimate $-0.07
52-week range
$0.83 – $2.74

IFRX analyst ratings

9 analysts
Strong buy
778%
Buy
111%
Hold
111%
Sell
00%
Strong sell
00%

Number of analysts at each rating.

IFRX price target

Price $1.32Target $7.68
52-week low $0.8352-week high $2.74

The average of analyst 12-month price targets compared with the latest close and the 52-week range.

IFRX earnings per share estimates

InflaRx N.V. EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current quarter (Sep '26)−$0.05−$0.08−$0.03−$0.18+71.1%5
Current fiscal year (2026)−$0.27−$0.30−$0.24−$0.68+60.9%5
Next fiscal year (2027)−$0.35−$0.48−$0.26−$0.27−30.1%5

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

IFRX revenue estimates

InflaRx N.V. revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current quarter (Sep '26)$0$0$0−100.0%7
Current fiscal year (2026)$0$0$0−100.0%7
Next fiscal year (2027)$0$0$00.0%7

IFRX EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

IFRX EPS estimate revisions

InflaRx N.V. EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current quarter (Sep '26)−$0.04−$0.05−$0.05−$0.05−$0.05+30.0%3 up · 0 down
Current fiscal year (2026)−$0.20−$0.30−$0.30−$0.30−$0.27+36.4%0 up · 1 down
Next fiscal year (2027)−$0.57−$0.37−$0.37−$0.37−$0.35−39.3%0 up · 1 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

IFRX earnings surprises

Reported EPSEstimate

Reported EPS vs the consensus estimate for the last 12 quarters; IFRX beat in 7 of 12.

What analysts expect from IFRX

9 analysts cover InflaRx; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.68, 481.9% above the latest close of $1.32. Analysts expect earnings of −$0.27 per share for 2026, +60.9% from a year earlier. For 2027 the average estimate is −$0.35 per share. InflaRx beat the EPS estimate in 7 of the last 12 quarters.

Related: IFRX income statement, IFRX key metrics, IFRX chart. See the IFRX stock overview for the latest quote and news.

IFRX forecast FAQ

What is InflaRx's price target?

The average analyst price target for InflaRx is $7.68, 481.9% above the latest close of $1.32.

Is InflaRx a buy, hold or sell?

Of 9 analysts covering InflaRx, 7 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.

What is InflaRx's EPS forecast?

Analysts forecast −$0.27 per share for 2026 (range −$0.30 to −$0.24); for 2027 the estimate is −$0.35.

When does InflaRx report earnings?

InflaRx is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $-0.07.

Does InflaRx usually beat earnings estimates?

InflaRx reported EPS at or above the analyst estimate in 7 of the last 12 quarters.

Biotechnology: forecast